Inhibitory Effects of the Lactobacillus rhamnosus GG Effector Protein HM0539 on Inflammatory Response Through the TLR4/MyD88/NF-кB Axis

• Published in: Frontiers in immunology Vol. 11; p. 551449
• Main Authors: Li, Yubin, Yang, Shaojie, Lun, Jingxian, Gao, Jie, Gao, Xuefeng, Gong, Zelong, Wan, Yu, He, Xiaolong, Cao, Hong
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 05.10.2020
• Subjects: Animals; colitis; Immunology; Inflammation - immunology; Inflammation - pathology; Inflammation - therapy; Inflammatory Bowel Diseases - immunology; Inflammatory Bowel Diseases - pathology; Inflammatory Bowel Diseases - therapy; inflammatory response; Lactobacillus rhamnosus - immunology; Lactobacillus rhamnosus GG; Mice; Myeloid Differentiation Factor 88 - immunology; NF-kappa B - immunology; postbiotics; RAW 264.7 Cells; Signal Transduction - immunology; TLR4/MyD88/NF-кB axis; Toll-Like Receptor 4 - immunology; inflammatory response; colitis; postbiotics; TLR4/MyD88/NF-кB axis; Lactobacillus rhamnosus GG
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2020.551449

Inflammatory bowel disease (IBD) is a chronic and relapsing intestinal inflammatory condition with no effective treatment. Probiotics have gained wide attention because of their outstanding advantages in intestinal health issues. In previous studies, a novel soluble protein, HM0539, which is derived from GG (LGG), showed significant protective effects against murine colitis, but no clear precise mechanism for this effect was provided. In this study, we hypothesized that the protective function of HM0539 might be derived from its modulation of the TLR4/Myd88/NF-κB axis signaling pathway, which is a critical pathway widely involved in the modulation of inflammatory responses. To test this hypothesis, the underlying anti-inflammatory effects and associated mechanisms of HM0539 were determined both in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages and in dextran sulfate sodium (DSS)-induced murine colitis. Our results showed that HM0539 inhibited the expression of cyclooxygenase-2 (COX-2) and the expression inducible nitric oxide synthase (iNOS) by down-regulating the activation of their respective promoter, and as a result this inhibited the production of prostaglandin E2 (PGE2) and nitric oxide (NO). Meanwhile, we demonstrated that HM0539 could ultimately modulate the activation of distal NF-κB by reducing the activation of TLR4 and suppressing the transduction of MyD88. However, even though the overexpression of TLR4 or MyD88 obviously reversed the effect of HM0539 on LPS-induced inflammation, HM0539 still retained some anti-inflammatory activity. Consistent with the findings, we found that HM0539 inhibited to a great extent the production of inflammatory mediators associated with the suppression of the TLR4/Myd88/NF-κB axis activation in colon tissue. In conclusion, HM0539 was shown to be a promising anti-inflammatory agent, at least in part through its down-regulation of the TLR4-MyD88 axis as well as of the downstream MyD88-dependent activated NF-κB signaling, and hence might be considered as a potential therapeutic option for IBD.